Traduction de «its other clinical and preclinical development programs » (Néerlandais → Français) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Significant investments were made in the first quarter of 2010 in R&D, including post-marketing commitments for A (H1N1) pandemic vaccines as well as the late-stage Menveo and MenB clinical development programs.
Au premier trimestre 2010, des investissements lourds ont été réalisés dans la R&D, comprenant des engagements ultérieurs à la vente pour les vaccins contre la pandémie de grippe A (H1N1) ainsi que des programmes de développement clinique ultime pour les vaccins Menveo et MenB.

Planned to initiate a Phase III clinical development program in chronic coronary heart disease in Q1 2011
Début d’un programme de développement clinique de phase III dans la maladie coronarienne chronique prévu

R&D investments (+1.0 percentage points) were lower as productivity initiatives more than offset investments in development programs for biosimilars as well as other differentiated generics, including oncology injectables and respiratory products.
Les investissements en R&D (+1,0 point de pourcentage) ont diminué car les gains de productivité ont plus que compensé les investissements dans les programmes de développement de biosimilaires ainsi que d’autres génériques différenciés, comprenant les injectables en oncologie et les produits contre les maladies des voies respiratoires.

The development of a medicine is a continuous process where the finetuning of the chemical–pharmaceutical process and the preclinical and clinical tests both occur in parallel and influence each other.
The development of a medicine is a continuous process where the finetuning of the chemical–pharmaceutical process and the preclinical and clinical tests both occur in parallel and influence each other.

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

Allied and Complementary Medicine Koninklijk Besluit Association des Chiropracticiens Belges Belgian School of Osteopathy (Wet) Beroepen in de Individuele Gezondheidszorg Bristish Medical Association Belgisch Staatsblad Complementary and Alternative Medicine Collège Belge d’Ostéopathie Council of Chiropractic Education Comité Européen de Normalisation/ European committee for Standardization Cumulative Index of Nursing and Allied Health Literature Centre for Reviews and Dissemination Debategraph Doctor in chiropractic Diplomed in osteopathy (USA: Doctor in osteopathy) Evidence Based Medicine European Council on Chiropractic Education European School of Osteopathy Flanders International College of Osteopathy Fonds voor Wetenschappelijk Onderzoek Facilitated Positional Release Graduate Education Program Groupement National Représentatif des Professionnels de l’Ostéopathie/ Groepering, Nationaal en Representatief van de Professionele Osteopaten Grading of Recommendations Assessment, Development and Evaluation High Velocity Low Amplitude International Academy of Osteopathy Intervalle de confiance/betrouwbaarheidsintervallen International Chiropractors Association Institut William Gardner Sutherland Muscle Energy Techniques Mean Weighted Difference National Institute for Health and Clinical Excellence Nederlands Register voor Osteopathie Non Steroidal Anti-inflammatory Drug Organisation Mondiale de la Santé Wereldgezondheidsorganisatie World Health Organisation Beroepscompetentieprofiel Physiotherapy Evidence Database Proprioceptive Neuromuscular Facilitation
Association Belge des Ostéopathes Classique / Belgische Associatie van Klassieke Osteopaten America Chiropractic Association Anglo-European College of Chiropractic Allied and Complementary Medicine Arrêté Royal Association des Chiropracticiens Belges Belgian School of Osteopathy (Wet) Beroepen in de Individuele Gezondheidszorg Bristish Medical Association Complementary and Alternative Medicine Collège Belge d’Ostéopathie Council of Chiropractic Education Comité Européen de Normalisation European committee for Standardization Cumulative Index of Nursing and Allied Health Literature Centre for Reviews and Dissemination Debategraph Doctor in chiropractic Diplomed in osteopathy (USA: Doctor in osteopathy) Evidence Based Medicine European Council on Chiropractic Education European School of Osteopathy Flanders International College of Osteopathy Fonds National de le Recherche Scientifique Facilitated Positional Release Graduate Education Program Groupement National Représentatif des Professionnels de l’Ostéopathie/ Groepering, Nationaal en Representatief van de Professionele Osteopaten Grading of Recommendations Assessment, Development and Evaluation High Velocity Low Amplitude International Academy of Osteopathy Intervalle de confiance International Chiropractors Association Institut William Gardner Sutherland Moniteur Belge Muscle Energy Techniques Mean Weighted Difference National Institute for Health and Clinical Excellence Nederlands Register voor Osteopathie Non Steroidal Anti-inflammatory Drug Organisation Mondiale de la Santé Profil de compétences professionnel Physiotherapy Evidence Database Proprioceptive Neuromuscular Facilitation Randomised Controlled Trial Roland Morris Disability Questionnaire